Mimi Kim, Sc.D.

Dr. Kim’s research focuses on statistical methods for designing and analyzing clinical trials and epidemiologic studies (research of the factors affecting health and illness).  Most clinical trials aim to demonstrate superiority of an experimental treatment relative to a standard treatment or placebo.  An increasing number of trials, however, seek to show that the effects of two treatments on a particular outcome are equivalent, or that one treatment is not inferior to another. These goals are of interest when the new therapy offers benefits such as reduced cost, toxicity, or invasiveness. Dr. Kim is investigating the effects of non-compliance, outcome misclassification and measurement error on equivalence and non-inferiority trials and developing new approaches for defining the non-inferiority margin. Her research interests also include the development of methods for analyzing multivariate and interval-censored survival data. In addition, she collaborates on studies in cancer, rheumatology, and HIV/AIDS.

Dr. Kim has been head of  the Division of Biostatistics since 2003 and also directs the Biostatistics Shared Resources in the Albert Einstein Cancer Center, the Institute of Clinical and Translational Research, and the Center for AIDS Research. She has served on numerous NIH grant review panels and is currently a member of the NIAMS AMSC Clinical Trials Review Committee.